Otarmeni

President Donald Trump highlighted 2-year-old Travis Smith, who regained hearing after a gene therapy treatment by Regeneron. The FDA granted accelerated approval for Regeneron's Otarmeni, a gene therapy administered surgically, which the company will provide free in the U.S. Trump also noted Regeneron's agreement to offer discounted drug prices.

President Donald Trump highlighted 2-year-old Travis Smith, who regained hearing through Regeneron's Otarmeni gene therapy, during a White House event. The FDA has granted accelerated approval for the treatment, which Regeneron will provide free in the U.S., though administration costs may apply. The therapy involves surgery similar to cochlear implantation.

A breakthrough gene therapy drug, Otarmeni, has received FDA approval and will be provided free to American children with total hearing loss. This development marks a significant advancement in treating congenital hearing impairment through gene therapy.